ESH MDS 2024 | Allo-SCT in older patients with MDS: selection, donors, and timing
In this video, Didier Blaise, MD, PhD, Institut Paoli-Calmettes, Marseille, France, discusses allogeneic stem cell transplantation (allo-SCT) in older patients with myelodysplastic syndromes (MDS). Historically, older patients with MDS have a poor prognosis due to a lack of available treatment options. However, allo-SCT can now be employed due to advances in the intensity of conditioning regimens and donor selection. Despite this, Dr Blaise highlights that the optimal timing for transplantation in these patients is not yet known and must be further investigated. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
